Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

ANN ARBOR, Mich., March 31 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company, today announced that it has completed enrollment in the Company's second pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets). Together with the previously completed first pivotal Phase 3 study of Ophena(TM), the Company has fully enrolled its planned pivotal Phase 3 studies for Ophena(TM), the most advanced estrogen-free oral therapy currently in development for the treatment of vaginal symptoms associated with menopause. A total of more than 1,700 patients were enrolled in these two pivotal studies at sites across the U.S. In accordance with the study design, all enrolled patients have received their first dose of either Ophena(TM) or placebo in the second Phase 3 clinical trial. Due to the high level of interest from patients and physicians, the Company chose to exceed its enrollment target of 750 patients. The Company expects to complete the study in late summer-2009 and these data, together with results from the first phase 3 study, will complete the efficacy requirements for an NDA filing under the published FDA guidance for vaginal atrophy.

"We are pleased to have achieved this important development milestone in the development of Ophena(TM) and to have exceeded our enrollment goal in only seven months, in what we believe to be the largest vaginal atrophy study ever conducted," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "We believe that the high interest in this study indicates a substantial need for new therapies for the treatment of postmenopausal vaginal atrophy."

The randomized, double-blind study has enrolled over 900 postmenopausal women at 116 trial centers throughout the United States. Women in the study are being treated with either a 60mg once daily oral dose of Ophena(TM) or placebo over the 12-week trea
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... Wis. , Dec. 23, 2014 PuraMed ... marketer of over-the-counter (OTC) medicinal and healthcare products, announced ... of MigraPure® H, a hemp-based, advanced headache relief product, ... dispensaries in Colorado , ... . With the MigraPure H Advanced headache ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... Governor has ignored their cost saving suggestionsHARRISBURG, Pa., Jan. ... suggestions on closing the state,s budget shortfall, SEIU Local ... workers across Pennsylvania, said they have identified millions of ... Governor should cancel contracts with private contractors for work ...
... craving a delicious frozen treat that won,t pack ... option at many local chain stores -- Skinny ... company, a manufacturer of innovative sports and nutritional ... distributors, retailers and online marketers nationwide.Skinny Dippers -- ...
... -- While some emerging technologies can create environments that ... researcher thinks games like Nintendo,s Wii Fit can help ... all ages. , "I think there is a great ... technology," said David Dzewaltowski, professor and head of the ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced today that ... Healthcare Conference on Wednesday, January 14, 2009 at 3 p.m. ... to be webcast live and may be accessed through a ... www.gen-probe.com . The webcast will be available for 30 days ...
... DIEGO, Jan. 6 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Healthcare Conference in San Francisco on Monday, January 12, ... Daniel M. Bradbury, president and chief executive officer ... live presentation and breakout session will be webcast, and ...
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... SB1518, an orally available, potent, and selective inhibitor of Janus ... S*BIO Pte Ltd based in Singapore. Under the terms ... develop and commercialize SB1518 (designated by Onyx as ONX 0803) ...
Cached Medicine News:Health News:State Human Services Union Identifies Ways to Save Millions of Tax Dollars 2Health News:Skinny Dippers(TM), First Zero-Calorie Frozen Dessert, Earns Widespread Retail, Online Distribution 2Health News:Wii Fit a promising tool for all ages 2Health News:Wii Fit a promising tool for all ages 3Health News:Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference 2Health News:Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO 2Health News:Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO 3Health News:Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO 4
Inquire...
Inquire...
... carefully inspects your equipment upon arrival. Our technician ... and provides you with a thorough customer quote. ... a tight budget so well help you prioritize ... repair begins., , ISI uses only OEM or ...
... The Infinity™ ALT single liquid ... in vitro quantitative determination of ALT ... patented formulation not only provides excellent ... precision and correlation against existing assays. ...
Medicine Products: